13th week of 2022 patent applcation highlights part 11 |
Patent application number | Title | Published |
20220096526 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF OCULAR DISEASES AND CONDITIONS - The invention relates to methods and compositions for use in the treatment and prevention of ocular diseases and conditions. | 2022-03-31 |
20220096527 | PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION - The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits hepatitis B virus (HBV) infections. The compound (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; and is identified as a compound that prevents, ameliorates and/or inhibits HBV infections. An inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing HBV infections; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of HBV infections is also provided. The present invention includes a 10-pharmaceutical composition for use in treatment and/or prevention of HBV infections, and a method for monitoring therapeutic success during treatment of HBV infections. | 2022-03-31 |
20220096528 | CYCLODEXTRIN DERIVATIVES IN THE TREATMENT OR PREVENTION OF LYSOSOMAL NEURODEGENERATIVE DISEASES - The present invention generally relates to use of single isomer chemically modified cyclodextrins, namely, S-(carboxyalkyl)-thio-cyclodextrin salts in medication used for the prevention or treatment of lysosomal storage diseases. | 2022-03-31 |
20220096529 | 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN (HPBETACD) FOR USE IN THE TREATMENT OF BREAST CANCER - A method including the step of administering 2-hydroxypropyl-β-cyclodextrin (HPβCD) for use in the treatment of breast cancer. Particularly, this invention relates to HPβCD for use in the treatment of triple negative breast cancer, wherein the HPβCD is for administration to a patient in need thereof. The invention extends to methods of preparing a pharmaceutical composition comprising HPβCD, and further extends to a method of treating breast cancer, typically triple negative breast cancer, by administration of the composition to a patient in need thereof. | 2022-03-31 |
20220096530 | SAFE BOVINE HEPARIN, PREPARATION METHOD, AND APPLICATION - The present invention relates to preparation method for the scale up production of a safe bovine heparin composed by a distinctively selected unfractioned bovine heparin polymers with low | 2022-03-31 |
20220096531 | EYE DROP FORMULATION WITH ENHANCED PROPERTIES BY COMBINING SODIUM HYALURONATE WITH CARBOXYMETHYLCELLULOSE - Embodiments described herein relate to formulations for and methods of use for eye drop formulations comprising carboxymethyl cellulose (CMC) and hyaluronic acid (HA) with an improved distribution on the cornea during blinking. | 2022-03-31 |
20220096532 | COMPOSITION FOR TREATING JOINT DISEASE AND KIT CONTAINING SAME - The present invention pertains to a composition for treating joint diseases and a kit including the same, and the purpose of the present invention is to provide a composition for treating joint diseases which can be used in patients with joint diseases, and a kit which includes the same. The present invention minimizes the burden on patients with chronic joint diseases while also achieving excellent medicinal effects by means of a composition for treating joint diseases which includes a modified hyaluronic acid having a group derived from an anti-inflammatory compound or a pharmaceutically acceptable salt of the modified hyaluronic acid, and which is used by being administered to patients with human joint diseases as a single injection per period of four or more weeks. | 2022-03-31 |
20220096533 | LIGNIN SOLVATION USING AQUEOUS BIOLOGICALLY COMPATIBLE BUFFERS - Provided are aqueous lignin solutions containing lignin solvated in Good's Buffers. The aqueous lignin solutions can be used in a variety of applications including biomedical research and in manufacturing a variety of lignin containing products including food grade and biomedical products. The aqueous lignin solutions can also be used in the treatment of microbial infection, as an adjuvant in antimicrobial therapeutics or therapy, and in forming antimicrobial products. Methods of making and using aqueous lignin solutions are also described. | 2022-03-31 |
20220096534 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION - Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. | 2022-03-31 |
20220096535 | COMBINATION DRUG THERAPIES OF PDE-5 INHIBITORS AND INHALED NITRIC OXIDE - Described are methods for treatment of hypertension in combination with pulsed, inhaled nitric oxide. | 2022-03-31 |
20220096536 | THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES - Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19. | 2022-03-31 |
20220096537 | METHODS FOR TREATING DILATED CARDIOMYOPATHY - The presently disclosed subject matter relates to methods of determining the risk of and treating the development of dilated cardiomyopathy (DCM) and to methods of preventing and/or reducing a risk of developing DCM in a dog or canine. In certain embodiments, the method comprises determining biomarkers comprising hematocrit, phosphate, alkaline phosphatase or creatinine. | 2022-03-31 |
20220096538 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREVENTION AND/OR TREATMENT OF INFLAMMATION - The disclosure relates to pharmaceutical compositions and methods for the prevention and/or treatment of inflammation, disease, and disorders. The treatment may include treatment of COVID-19. | 2022-03-31 |
20220096539 | SALT NANOPARTICLES AND COMPOSITIONS AND METHODS OF USE THEREOF - Particles formed from an alkai metal or alkaline earth metal and halide, for example, sodium and chloride, are provided. The particles can have a hydrophilic coating or external layer, formed of, for example, a polyether-lipid conjugate. In preferred embodiments, the lipid is a phospholipid such as a phosphoethanolamine, and the polyether is a polyethylene glycol such as a PEG amine. Methods making the particles by, for example, a microemulsion reaction, are also provided. Pharmaceutical compositions including a plurality of particles and a pharmaceutically acceptable carrier are also disclosed. Typically the compositions include an effective amount of particles to treat a disease or condition, particularly cancer, in a subject in need thereof. The particles are typically nanoparticles, for example, between about 10 nm and 250 nm and can be monodisperse. | 2022-03-31 |
20220096540 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF LYSOSOMAL STORAGE DISORDERS - Provided is a method for prevention or treatment of a lysosomal storage disorder, and more particularly, to a method that may exhibit excellent efficacy against various lysosomal storage disorders including Niemann-Pick disease by including graphene quantum dots. | 2022-03-31 |
20220096541 | METHODS TO TREAT MITOCHONDRIAL-ASSOCIATED DYSFUNCTIONS OR DISEASES - Methods for the treatment of disorders associated with mitochondrial dysfunction, including rare, inborn errors of metabolism caused by genetic mutations; neurodegenerative disease; diabetes; and aging and age-associated decline. Generally, the methods include administering a therapeutically effective amount of one or more treatments that (i) induce hemoglobin “left-shifting” and/or (ii) induce anemia, as described herein, to a subject who is in need of, or who has been determined to be in need of, such treatment. | 2022-03-31 |
20220096542 | AUGMENTATION OF NATURAL KILLER CELL ACTIVITY AND INDUCTION OF CYTOTOXIC IMMUNITY USING LEUKOCYTE LYSATE ACTIVATED ALLOGENEIC DENDRITIC CELLS: STEMVACS - Stimulation of immunity would be beneficial in various chronic conditions such as viral infections and neoplasia. Autologous dendritic cell therapy has been widely described in the immunotherapy literature and has been approved by the FDA for treatment of prostate cancer. Unfortunately, the need to generate individual doses is costly and limited by ability of the patients to have sufficient starting cell numbers available to generate sufficient dendritic cells. Here we describe the process of preparing allogeneic dendritic cells utilizing a leukocyte lysate based approach. These data support development of StemVacs for conditions that would benefit from NK activation such as cancer and COVID-19. | 2022-03-31 |
20220096543 | TOLLIP DEFICIENT NEUTROPHILS AND USES THEREOF - Described herein are modified cells and compositions thereof, wherein the cells can have reduced or eliminated Tollip gene and/or protein expression. In some embodiments, the modified cells can be neutrophils. Also described herein are methods of making and using the modified cells and compositions thereof. In some embodiments, the modified cells having reduced or eliminated Tollip gene and/or protein expression can be administered to a subject in need thereof. | 2022-03-31 |
20220096544 | CHEMOKINE EXPRESSING CELL AND USE THEREOF - The present invention relates to a chemokine expressing cell. Said cell expresses an exogenous IL-21R binding protein or an exogenous IL-21 and an exogenous chemokine. Further provided is a cell expressing an exogenous receptor, an exogenous IL-21R binding protein or an exogenous IL-21 and an exogenous chemokine. The cell involved is not only effective in solid tumor cells in vitro, but also has an excellent killing effect on solid tumor cells in vivo. | 2022-03-31 |
20220096545 | NANOPARTICLE FORMULATIONS - This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment. | 2022-03-31 |
20220096546 | Modified Cell Expansion and Uses Thereof - The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, a method of enhancing T cell-based therapy comprises administering a mixed population of T cells comprising modified T cells comprising a first chimeric antigen receptor (CAR) and modified T cells comprising a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell. | 2022-03-31 |
20220096547 | MODIFIED IMMUNE CELLS EXPRESSING FLAGELLIN POLYPEPTIDE - Provided are modified immune cells expressing a flagellin polypeptide capable of binding to a toll-like receptor. The modified immune cell further comprises an engineered receptor. Also provided are methods and pharmaceutical compositions for cancer treatment using the modified immune cells. | 2022-03-31 |
20220096548 | MODIFIED IMMUNE CELLS CO-EXPRESSING CHIMERIC ANTIGEN RECEPTOR AND IL-6 ANTAGONIST FOR REDUCING TOXICITY AND USES THEREOF IN ADOPTIVE CELL THERAPY - A population of immune cells comprising modified immune cells co-expressing a chimeric antigen receptor and an IL-6 signaling antagonist (e.g., an anti-IL6 or anti-IL-6R antibody) and optionally an IL-1 signaling antagonist. Also provided herein are methods of producing such immune cell populations comprising the modified immune cells and methods of using such in cell therapy (e.g., to treat cancer, infectious diseases, or immune diseases). | 2022-03-31 |
20220096549 | CHIMERIC CYTOKINE RECEPTORS - Some embodiments of the methods and compositions provided herein relate to chimeric cytokine receptors. In some embodiments, a chimeric cytokine receptor can include an IL-7 tethered to an extracellular IL-7 receptor domain, and an intracellular IL-21 receptor domain linked to the extracellular IL-7 receptor domain. In some embodiments, a T cell containing a chimeric cytokine receptor can be readily activated and/or expanded in the absence of an exogenous cytokine. | 2022-03-31 |
20220096550 | USE OF EXOSOME DERIVED FROM DECIDUAL NATURAL KILLER (dNK) CELLS OR dNK CELL SUBSET IN PREPARATION OF DRUG AND AUXILIARY THERAPEUTIC AGENT FOR INFERTILITY-RELATED DISEASES - Use of an exosome derived from decidual natural killer (dNK) cells or a dNK cell subset in the preparation of a drug and an auxiliary therapeutic agent for infertility-related diseases is provided. Experiments have confirmed that the exosome treats the endometrial growth disorder-related diseases by promoting increase of endometrial thickness, increasing endometrial cell viability, reducing endometrial cell damage, promoting VEGF expression, and maintaining stemness and stimulating proliferation of endometrial stromal cells, such that a conception rate for endometrial injury model mice increases from 20% to 50%-70%; and the exosome treats the maternal-fetal immune tolerance disorder-related diseases by exerting immune tolerance, reducing a spontaneous abortion rate, and increasing a helper T cell level. In addition, the exosome effectively increases the development rate of eggs fertilized in vivo or in vitro in a multiplying way, and improves an implantation rate and a birth rate for in vitro fertilization and embryo transfer. | 2022-03-31 |
20220096551 | COMBINATIONS, NANOPARTICLES AND METHODS FOR CONTROLLING NATURAL KILLER CELL ACTIVATION AND FUNCTION - The invention relates to combinations comprising at least one compound that inhibits the expression, activity and/or stability of at least one SHP protein and at least one Cbl protein, as well as nano-particles, cells and composition thereof. The combinations of the invention are used in methods for activating NK cells and/or T cells and for treating immune-related disorders. | 2022-03-31 |
20220096552 | METHOD AND COMPOSITION FOR PREDICTING LONG-TERM SURVIVAL IN CANCER IMMUNOTHERAPY - Provided is a peripheral blood biomarker for predicting the long-term survival/need for therapeutic intervention in cancer immunotherapy. The present invention provides a method that uses a composition of a cell subpopulation in a sample obtained from a subject as an indicator to predict the long-term survival of the subject in cancer immunotherapy. The long-term survival/need for therapeutic intervention in a subject in cancer immunotherapy can be predicted by comparing the level of a CD4+ T cell subpopulation that correlates with dendritic cell stimulation in an antitumor immune response or a dendritic cell subpopulation that correlates with dendritic cell stimulation in an antitumor immune response with a reference standard. | 2022-03-31 |
20220096553 | METHODS OR GENERATING T-CELLS FROM STEM CELLS AND IMMUNOTHERAPEUTIC METHODS USING THE T-CELLS - Methods and composition for production of T cells are provided. Also provided are therapeutic methods using engineered T cells. For example, in certain aspects methods include preparing three dimensional cell culture compositions comprising stroma cells and hematopoietic stem or progenitor cells in a serum-free medium for producing T cells. | 2022-03-31 |
20220096554 | POOLED NK CELLS FROM UMBILICAL CORD BLOOD ASSOCIATED WITH ANTIBODIES AND THEIR USES FOR THE TREATMENT OF DISEASE - The invention relates to the field of cell therapy, particularly NK cell mediated therapy associated with antibodies. The present invention is directed to methods and compositions for increasing the efficiency of therapeutic natural killer cells (NK cells) and/or antibodies, wherein said methods or compositions comprise the use of pooled NK cells from umbilical cord blood units (UCBs), preferably alloreactive NK cells, in combination with a therapeutic antibody in order to enhance the efficiency of the treatment in human subjects, in particularly through an increase in antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism. The present invention relates to said composition as a pharmaceutical composition, preferably for its use for the treatment of a disease in a human subject in need thereof, preferably wherein said disease is a cancer, infectious or immune disease. Finally, the present invention is also directed to a method of treatment of a disease in a human subject in need thereof, comprising the administering to said subject said pooled NK cells from UCBs, preferably alloreactive, in combination with a therapeutic antibody which can be bound to said NK cells. | 2022-03-31 |
20220096555 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES - The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation. | 2022-03-31 |
20220096556 | PRODUCTION OF MEGAKARYOCYTES OR PLATELETS FROM MONOCYTES - We disclose a method, comprising extracting cells from a tissue of a donor, wherein the tissue is selected from the group consisting of blood and bone marrow; isolating CD14 | 2022-03-31 |
20220096557 | METHOD FOR TREATING OSTEOARTHRITIS - Disclosed herein is a method for treating an osteoarthritis in a subject in need thereof. The method mainly includes administering to the subject an effective amount of isolated mitochondria. According to some embodiments of the present disclosure, the isolated mitochondria are administered to the subject in need in the amount of about 1 mg/kg to about 100 mg/kg. | 2022-03-31 |
20220096558 | SYSTEMIC, ALLOGENIC STEM CELL THERAPIES FOR TREATMENT OF DISEASES IN ANIMALS - A method for treating preselected diseases comprising the steps of providing a therapeutic dose of a mesenchymal stem cell composition, the mesenchymal stem cell composition comprising mesenchymal stem cells harvested from at least one tissue selected from the group consisting of placental tissue, bone marrow, dental tissue, testicle tissue, and dermal tissue; and systemically administering the mesenchymal stem cell composition to the patient suffering from a preselected disease or diseased state through an intravenous injection. | 2022-03-31 |
20220096559 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS - The invention provides compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a donor, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various stem cell disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. In certain embodiments, the compositions and methods described herein lead to the mobilization of a population of CD34 | 2022-03-31 |
20220096560 | METHODS AND COMPOSITIONS RELATING TO MESENCHYMAL STEM CELL EXOSOMES - The invention provides compositions comprising mesenchymal stem cell (MSC) derived exosomes, and methods of their use in subjects having certain lung diseases including inflammatory lung disease. | 2022-03-31 |
20220096561 | INHIBITING OR ALLEVIATING AGENT FOR INFLAMMATION IN THE BRAIN - An inhibiting or alleviating agent for inflammation in the brain comprising an extract from inflamed tissue inoculated with vaccinia virus as the active ingredient. In another aspect, the invention relates to a determination or evaluation method of an extract from inflamed tissue inoculated with vaccinia virus or an agent comprising the extract, characterized in that the inhibition of the expression of pro-inflammatory cytokines and/or NF-κB pathway related proteins induced by the promotion of expression of BDNF in cultivated glial cells is used as an indicator. In still another aspect, the invention also relates to a use of an extract from inflamed tissue inoculated with vaccinia virus in the production of the inhibiting or alleviating agent for inflammation in the brain. | 2022-03-31 |
20220096562 | OSTEOBLAST CELL-MIXTURE, AND IMPLEMENTATIONS THEREOF - The present disclosure provides a method for obtaining osteoblast cell-mixture which can be used for transplantation of osteoblast cells in a subject. The present disclosure further discloses a method for delivering osteoblast cells into a subject. The method for obtaining osteoblast cell-mixture as disclosed herein is devoid of any additives like calcium chloride and aprotinin. The method for delivering osteoblast cells as disclosed herein provides bone regeneration in the subject. | 2022-03-31 |
20220096563 | COMPOSITION FOR TREATING INFLAMMATORY DISEASE INDUCED BY HYPERIMMUNE RESPONSE - A composition according to an embodiment of the present application includes at least one of a chondrocyte and a cell capable of differentiating into a chondrocyte, and a cell into which a gene encoding TGF-β1 is introduced and derived from human embryonic kidney 293 (HEK-293) cell. The composition may be used for treating an inflammatory disease induced by a hyperimmune response. | 2022-03-31 |
20220096564 | METHODS AND COMPOSITIONS FOR TREATMENT OF BONE DEFECTS WITH PLACENTAL CELL POPULATIONS - Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells. | 2022-03-31 |
20220096565 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - The invention provides compositions comprising bacterial strains for treating and preventing a neurodegenerative disorder. | 2022-03-31 |
20220096566 | THERAPEUTIC MICROBIOTA FOR THE TREATMENT AND/OR PREVENTION OF DYSBIOSIS - Disclosed are methods and compositions for the prevention and treatment of dysbiosis and associated conditions. In particular, described herein are compositions of microbial consortia, including minimal microbial consortia, that can prevent and/or cure dysbiosis and associated conditions. In certain embodiments, the microbial consortia comprise certain members of the taxa Clostridiales, Bacteroidetes, | 2022-03-31 |
20220096567 | METHODS AND COMPOSITIONS FOR REDUCING VANCOMYCIN-RESISTANT ENTEROCOCCI INFECTION OR COLONIZATION - The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria | 2022-03-31 |
20220096568 | COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS - It was found that bacteria belonging to the genus | 2022-03-31 |
20220096569 | PROBIOTIC SPORTS NUTRITION COMPOSITIONS - The present application relates to nutritional compositions comprising lactic acid-producing bacteria. | 2022-03-31 |
20220096570 | LACTOBACILLUS PLANTARUM WITH COLORECTAL CANCER INHIBITION FUNCTION AND USE THEREOF - The present invention relates to the technical field of microbes, in particular to a | 2022-03-31 |
20220096571 | POSTBIOTIC EXTRACT AND PREPARATION PROCESS AND USE THEREOF - Disclosed herein is a process for producing a postbiotic extract, which includes providing a first material having a first isoelectric point ranging from pH 1 to pH 6 and a second material having a second isoelectric point ranging from pH 4 to pH 8, admixing the first material and a probiotic microorganism with water having a pH greater than the second isoelectric point, so as to form a mixture, adding the second material into the mixture and then adjusting a pH of the second material-added mixture to between the first and second isoelectric points so that a precipitate is formed, and subjecting the precipitate to a cell wall isolation treatment to obtain the postbiotic extract. Use of the postbiotic extract is also disclosed. | 2022-03-31 |
20220096572 | METHOD FOR ALLEVIATING ARTHRITIS WITH POSTBIOTIC EXTRACT - A method for alleviating arthritis includes administering to a subject in need thereof a postbiotic extract. The postbiotic extract is prepared by a process including the steps of providing a first material having a first isoelectric point ranging from pH 1 to pH 6 and a second material having a second isoelectric point ranging from pH 4 to pH 8, admixing the first material and a probiotic microorganism with water having a pH greater than the second isoelectric point, so as to forma mixture, adding the second material into the mixture and then adjusting a pH of the second material-added mixture to between the first and second isoelectric points so that a precipitate is formed, and subjecting the precipitate to a cell wall isolation treatment to obtain the postbiotic extract. | 2022-03-31 |
20220096573 | METHOD FOR IMPROVING SKIN CONDITION WITH POSTBIOTIC EXTRACT - A method for improving skin condition includes administering to a subject in need thereof a postbiotic extract. The postbiotic extract is prepared by a process including the steps of providing a first material having a first isoelectric point ranging from pH 1 to pH 6 and a second material having a second isoelectric point ranging from pH 4 to pH 8, admixing the first material and a probiotic microorganism with water having a pH greater than the second isoelectric point, so as to forma mixture, adding the second material into the mixture and then adjusting a pH of the second material-added mixture to between the first and second isoelectric points so that a precipitate is formed, and subjecting the precipitate to a cell wall isolation treatment to obtain the postbiotic extract. | 2022-03-31 |
20220096574 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING CENTRAL NERVOUS SYSTEM DISORDERS AND OTHER CONDITIONS CAUSED BY GUT MICROBIAL DYSBIOSIS - The technology described herein is directed to compositions and methods for treating CNS diseases or disorders associated with microbiome dysbiosis. In one aspect, described herein are compositions and methods for treating CNS diseases or disorders associated with a microbiome deficient in queuine biosynthesis. In another aspect, described herein are compositions and methods for treating CNS diseases or disorders associated with a microbiome deficient in endozepine biosynthesis. In another aspect, described herein are compositions and methods for treating CNS diseases or disorders associated with a microbiome deficient in heavy metal sequestration. | 2022-03-31 |
20220096575 | MODULATION OF MICROBIAL SYNTHESIS OF 4-ETHYLPHENOL AND 4-ETHYLPHENYL SULFATE IN BEHAVIOR AND DISEASE - Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset, or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject. | 2022-03-31 |
20220096576 | Methods of Identifying Bacteriophages that can Infect and Kill Host-Adapted Pathogenic Bacteria - The subject matter of the instant invention relates to methods of enhancing harvesting of phages against a targeted host bacteria, as well as methods of identifying phages likely to have an enhanced propensity to infect and kill an infectious pathogenic bacteria in vivo, from samples comprising phages. The invention also relates to phage libraries, pharmaceutical compositions, methods of treatment, and phage-based diagnostic methods and methods of detecting bacteria related thereto. | 2022-03-31 |
20220096577 | ONCOLYTIC ADENOVIRUS COMPOSITIONS - An adenovirus comprising an E1A polypeptide comprising one or more modifications and comprising an E4orf6/7 polypeptide comprising one or more modifications is described. Compositions and kits comprising the modified adenoviruses are also described. Further described is a method of treating a proliferative disorder in a subject comprising administering to the subject an adenovirus comprising the E1A polypeptide comprising one or more modifications and comprising the E4orf6/7 polypeptide comprising one or more modifications. | 2022-03-31 |
20220096578 | COMPOSITIONS AND METHODS OF USING STAT1/3 INHIBITORS WITH ONCOLYTIC HERPES VIRUS - The present disclosure relates to the use of an oncolytic virus, such as HSV, and a STAT1/3 inhibitor, such as nifuroxazide and C16, in the treatment of cancer. Therapeutic compositions are provided that may be used to prevent, treat, or ameliorate the effects of a targeted cancer. Methods of using such compositions are also disclosed, such as methods of using the therapeutic compositions for improving efficacy of an oncolytic virotherapy (and for preventing macrophage and microglia inhibition of oncolytic viral activity). | 2022-03-31 |
20220096579 | Production and Use of Yeast Extract as a Medical Adjuvant - The present invention relates to compositions and methods for enhancing bioavailability of health-promoting compounds, such as pharmaceuticals and nutritional supplements. The subject invention utilizes an adjuvant composition comprising yeast extract to enhance bioavailability of health-promoting compounds and to reduce the effective dosage that is required. | 2022-03-31 |
20220096580 | METHOD FOR STIMULATING GROWTH OF BACTERIA IN THE GUT MICROBIOTA OF A MAMMAL - A method is for stimulating the growth of bacteria of the Bacteroidetes phylum in the gut microbiota of a mammal. The method includes administering a yeast product as a prebiotic agent to the mammal. The yeast product comprises the walls of yeast cells, such as those of the genera | 2022-03-31 |
20220096581 | CANNABINOIDS INFUSED CONSUMABLES - The present disclosure is directed to cannabinoids infused coffee beans, nuts, and seeds consumables and methods of producing the cannabinoid infused consumables. The consumables are infused in an overall two-step process, in which cannabinoids from a | 2022-03-31 |
20220096582 | CANNABINOIDS INFUSED CONSUMABLES AND NON-CONSUMABLES - The present disclosure is directed to cannabinoids infused consumables and non-consumables and methods of producing the cannabinoid infused consumables and non-consumables. The consumables are infused in an overall two-step process, in which cannabinoids from a | 2022-03-31 |
20220096583 | CANNABINOIDS INFUSED COFFEE BEANS AND RAW NUTS - The present disclosure is directed to whole spectrum cannabinoids infused coffee beans or raw nuts and methods of producing the cannabinoids infused coffee beans or raw nuts. The coffee beans or raw nuts are infused in an overall two-step process, in which cannabinoids from a | 2022-03-31 |
20220096584 | CANNABINOIDS INFUSED CONSUMABLES - The present disclosure is directed to cannabinoids infused consumables, including cacao beans, dehydrated fruit, and raw popcorn kernels, along with methods of producing the cannabinoid infused cacao beans, dehydrated fruit, and raw popcorn kernels. The consumables are infused in an overall two-step process, in which cannabinoids from a | 2022-03-31 |
20220096585 | METHOD FOR PREPARING DRINKING WATER FOR LIVESTOCK TO CREATE ENVIRONMENT FOR REVITALIZING INTESTINAL EFFECTIVE MICROORGANISMS USING TREATMENT OF COMPONENTS VIA ION EXCHANGE OF NATURAL MINERALS - Disclosed is a method for preparing drinking water for livestock to create an environment for revitalizing intestinal effective microorganisms using treatment of components via ion exchange of natural minerals. The method includes S | 2022-03-31 |
20220096586 | PHARMACEUTICAL COMPOSITION COMPRISING A FRACTION OF MELISSA OFFICINALIS LEAF EXTRACT - The present invention relates to a pharmaceutical composition for preventing or treating otitis media with effusion comprising a fraction of Melissa officinalis leaf extract as an effective ingredient. | 2022-03-31 |
20220096587 | Compositions and Methods for Treating and Preventing Helicobacter Pylori Infections - The present invention provides compositions and methods for treating subject infected with | 2022-03-31 |
20220096588 | SYNERGISTIC COMPOSITION FOR OSTEOARTHRITIS - A method for treating a disease condition such as inflammation, arthritis, joint pain, rheumatoid arthritis, osteoarthritis, chronic non-rheumatoid arthritis, and collagen degradation in a patient in need thereof involves administering to the patient an effective amount of a composition: | 2022-03-31 |
20220096589 | METHODS OF TREATING CERVICAL CANCER - A treatment of cervical tumor caused by human papillomavirus (HPV) infection is disclosed. Methods for improving treatment of cervical tumor caused by HPV infection are also disclosed. The methods include administering a polynucleotide encoding an E6/E7 fusion protein to a subject suffering from cervical tumor caused by HPV. The cervical tumor may be squamous cell carcinoma (SCC), adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, neuroendocrine tumor (NET), glassy cell carcinoma, villoglandular adenocarcinoma (VGA), non-carcinoma malignancies, melanoma, lymphoma, or cervical intraepithelial neoplasia (CIN). | 2022-03-31 |
20220096590 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS - The present invention relates to MEK inhibitor, p38 inhibitor and/or NFκB inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. In addition an in vitro test system, wherein the test system comprises cultured cells infected with an influenza virus and a bacterium or with a bacterium alone is provided. | 2022-03-31 |
20220096591 | ANTIMICROBIAL COMPOUNDS FROM THE GENUS DELFTIA - Cultures of | 2022-03-31 |
20220096592 | PIC1 VARIANTS WITH IMPROVED SOLUBILITY AND METHODS OF USING THE SAME - A method of improving the lifespan of transfused platelets is described. The method may be useful for patients with alloimmunozation who are refractory to transfused platelets. A method of treating delayed hemolytic transfusion reaction is also described. Also described are PIC1 peptide variants with improved solubility and activity. | 2022-03-31 |
20220096593 | METHOD AND COMPOSITIONS COMPRISING A CT20 PEPTIDE - Disclosed herein are compositions comprising a CT20 peptide and methods of using the disclosed compositions to treat cancers expressing chaperonin containing TCP (CCT). | 2022-03-31 |
20220096594 | MACROCYCLIC PEPTIDES FOR TARGETED INHIBITION OF AUTOPHAGY - Provided herein are cyclic peptide inhibitors of autophagy that bind to LC3. These cyclic peptides may be used to treat diseases or disorders associated with autophagy, such as, for example, cancer, diabetes, cardiovascular disease, and neurological disorders. These cyclic peptides may also be used to sensitize cancers to front-line chemotherapy, immunotherapy, and/or radiation therapy. | 2022-03-31 |
20220096595 | ANTI-ATOPIC DERMATITIS PROTEIN - Provided is an anti-atopic dermatitis protein. A corresponding pharmaceutical composition contains a pharmaceutically acceptable carrier and the anti-atopic dermatitis protein. The anti-atopic dermatitis protein is one or more proteins selected from the group consisting of | 2022-03-31 |
20220096596 | METHOD OF TREATING AMD IN PATIENTS REFRACTORY TO ANTI-VEGF THERAPY - Disclosed herein are methods for the treatment of a patient having an ocular conditions such as age-related macular degeneration or diabetic macular edema through administration of a recombinant binding protein comprising an ankyrin repeat domain. In some embodiments, the composition may be administered every 8 weeks to every 16 weeks. In some embodiments, the patient being treated may be refractory to existing anti-VEGF therapies. | 2022-03-31 |
20220096597 | CARDIO-PROTECTIVE EFFECT OF VASOCONSTRICTION-INHIBITING FACTOR (VIF) - The present invention relates to a vasoconstriction-inhibiting factor (VIF) or a nucleic acid encoding it for the prevention and/or treatment of consequences of a heart disease. Furthermore, the present invention relates to pharmaceutical compositions containing the VIF and targeted (combination) therapies, in particular using the pharmaceutical compositions according to the invention. The present invention further relates to a kit for non-therapeutic in-vitro use containing the VIF or a nucleic acid encoding it. | 2022-03-31 |
20220096598 | FIBROBLAST GROWTH FACTOR 21 VARIANT, AND FUSION PROTEIN AND USE THEREOF - It discloses a fibroblast growth factor 21 variant, a fusion protein comprising such fibroblast growth factor 21 variant, a GLP-1 variant and a FC sequence, and a use thereof. The fusion protein of the present invention has high activity, long half-life and a novel structure, and can significantly decrease blood sugar, body weight, and improve fat metabolism. The present invention also provides a fusion gene, an expression construct, and a host cell comprising an encoding nucleotide sequence of the fusion protein, and a use of the fusion protein, the fusion gene, the expression construct, the host cell, and the pharmaceutical composition in the preparation of drugs for treating obesity, hyperlipidemia, diabetes, and cardiovascular and cerebrovascular diseases. | 2022-03-31 |
20220096599 | METHOD FOR PREVENTING, TREATING OR DELAYING MYOCARDIAL DAMAGE USING NEUREGULIN AND COMPOSITION - A method for preventing, treating or delaying myocardial damage in a mammal using neuregulin and a composition. An administration method for, an administration frequency of and an administration dosage of a pharmaceutical formulation or composition for reducing myocardial damage. It can be proved in a rat myocardial damage model that neuregulin can improve the cardiac function after myocardial infarction, suggesting that neuregulin can be used for preventing, treating, or delaying myocardial infarction damage. | 2022-03-31 |
20220096600 | PERIOSTEAL SKELETAL STEM CELLS IN BONE REPAIR - Embodiments of the disclosure encompass methods and compositions for bone repair and bone injury healing. In some embodiments, the bone repair and bone injury healing utilizes the enhancement of migration of certain types of bone cells upon stimulation by a particular cytokine. In specific embodiments, migration of periosteal skeletal stem cells upon delivery of CCL5 and/or TNFα is enhanced and fosters bone repair and healing. | 2022-03-31 |
20220096601 | COMBINATION IMMUNOTHERAPY DOSING REGIMEN FOR IMMUNE CHECKPOINT BLOCKADE - The present disclosure provides a method of treating cancer with a priming dose of combination immunotherapy comprising IL-2 (e.g., extended-PK IL-2), an immune checkpoint inhibitor, a tumor targeting antibody or integrin-binding polypeptide, and optional cancer vaccine, administered prior to maintenance doses of immune checkpoint inhibitor therapy. The methods of the disclosure can be used to treat a broad range of cancer types. | 2022-03-31 |
20220096602 | LIF THERAPY FOR INDUCING INTESTINAL EPITHELIAL CELL REGENERATION - Disclosed herein are new therapeutic methods and compositions for maintaining and regenerating intestinal epithelial cells in a mammal. In a specific embodiment, the methods involve administering an amount LIF that induces intestinal epithelial cell regeneration. The methods and compositions are useful for preventing or treating gastrointestinal radiation injury or GVHD. | 2022-03-31 |
20220096603 | INSULIN FORMULATIONS AND USES IN INFUSION DEVICES - Embodiments of the present disclosure provide insulin formulations having a near neutral pH and improved pharmacokinetic/pharmacodynamic properties, and uses in insulin infusion devices that may provide extended infusion period up to 7-14 days. Also provided are systems for administering insulin, the system may include a first reservoir, a second reservoir, an insulin pump configured to administer contents of the first reservoir or the second reservoir, and one or more hardware processors in communication with the insulin pump. | 2022-03-31 |
20220096604 | USE OF IGFBP7 FOR TREATING MALARIA - The invention relates to a composition comprising insulin growth factor binding protein 7 (IGFBP7) for treating malaria or reducing the phenomenon of IRB C-endothelial cytoadherence. The composition can further comprise Von Willebrand Factor (VWF) and/or thrombospondin-1 (TSP-1). The composition can also be used as an adjunct therapeutic agent alongside other anti-malarial drugs. | 2022-03-31 |
20220096605 | THERAPEUTIC SYSTEMS, DEVICES, AND COMPOSITIONS WITH WOUND HEALING AND TISSUE REGENERATIVE PROPERTIES, USES THEREOF, AND CORRESPONDING METHODS - Presented herein are compositions that can be administered to a subject having damaged tissue, for example a wound. The compositions are often administered in combination with administration of energy (e.g., laser energy, light from a light emitting diode, radiofrequency (RF) energy, audio frequency energy, etc.) from an energy generating device and/or system to the affected site. The compositions, systems, devices, and methods herein were found to induce wound healing and tissue regeneration. | 2022-03-31 |
20220096606 | Compositions and Methods for Treatment of Duchenne Muscular Dystrophy - Compositions and methods for treating Duchenne Muscular Dystrophy (DMD) are encompassed. | 2022-03-31 |
20220096607 | SUBCUTANEOUS THERAPEUTIC ENZYME FORMULATIONS, USES, AND METHODS FOR GENERATING THEREOF - Provided herein are compositions containing a lysosomal storage disorder replacement enzyme (LSDRE) and a dispersing agent for subcutaneous injection for treatment of lysosomal storage diseases. Kits and methods of treatment are also provided. | 2022-03-31 |
20220096608 | FIBRINOLYTIC COMPOSITION AND METHOD OF ITS PREPARATION - The present invention discloses modified forms of plasmin with advantageous properties. As compared to their natural unmodified form, these variants exhibit significantly modulated kinetics in terms of delayed inhibition characteristics in the presence of specific inhibitors, such as α | 2022-03-31 |
20220096609 | COMBINATION THERAPY USING CLOSTRIDIAL TOXIN DERIVATIVE AND AT LEAST ONE CHEMICAL DEPOLARIZING AGENT - Formulations, methods, and kits comprising at least one Clostridium toxin derivative and at least one chemical depolarizing agent suitable for inducing local, partial or complete muscle paralysis or muscle denervation in a subject are described. | 2022-03-31 |
20220096610 | METHODS OF TREATMENT FOR CERVICAL DYSTONIA - This invention provides methods to treat or prevent cervical dystonia, a disorder related thereto, or a symptom thereof, with novel injectable compositions comprising botulinum toxin that may be administered to a subject suffering from such maledy. The injectable compositions and methods in which these compositions are used provide novel and advantageous treatments which result in high responder rates and long duration of effect, for example, a duration of effect for 24 weeks and longer. | 2022-03-31 |
20220096611 | ENZYME COMPOSITIONS AND USE THEREOF FOR WOUND HEALING - Compositions and methods of using the compositions for wound healing are provided. The compositions include one or more digestive enzymes, for example, one or more protease, lipases, and amylases. The compositions can be formulated as topical pharmaceutical compositions and can be used for faster healing through stimulation of epidermal cells in the absence of scarring. The compositions may deposit a short-term fibrosis and help prevent re-opening of wounds. The compositions may improve recruitment of white blood cells, thereby inducing or enhancing growth factor and immune system activation via an enzyme antibiotic effect. The compositions may enhance the epidermal integrity beyond that of the normal physiological restorative process. Application of the compositions may result in greater re-growth of hair on regions of wounds healed with enzyme and reduced alopecia. The compositions may be administered without causing allergic reactions and without causing biological damage or burns. | 2022-03-31 |
20220096612 | METHODS FOR INDUCING IMMUNE TOLERANCE - The invention is based on the discovery that unmodified mRNA encapsulated in a liposome that is preferentially directed to the liver is particularly effective at inducing immune tolerance in a subject and avoids the need for co-administering an immune regulator (either separately or in form of an mRNA encoding the immune regulator). The invention therefore provides methods for inducing immune tolerance to one or more peptides, polypeptides or proteins in a subject in need thereof, wherein said method comprises administering to the subject one or more mRNAs, each mRNA comprising a 5′UTR, a coding region and a 3′UTR, wherein the one or more coding regions of the one or more mRNAs encode the one or more peptides, polypeptides or proteins, wherein said one or more mRNAs are encapsulated in one or more liposomes, wherein upon administration the one or more liposomes are preferentially delivered to the liver of the subject, wherein the nucleotides of the one or more mRNAs are unmodified. | 2022-03-31 |
20220096613 | NOVEL TRYPANOSOMAL VACCINE - The invention relates to a trypanosomal vaccine, to pharmaceutical compositions comprising said vaccine and to their uses in vaccination to prevent trypanosomal infection in a mammal. | 2022-03-31 |
20220096614 | PEPTIDE-INDUCED NK CELL ACTIVATION - The invention relates to a method of treatment or prophylaxis of cancer, wherein the cancer overexpresses exportin-1, the method comprising the administration of: a peptide capable of activating NK cell-mediated immunity to cancer cells that overexpress exportin-1, the peptide comprising or consisting of the amino acid sequence X | 2022-03-31 |
20220096615 | COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL DYSFUNCTION - The present invention is directed to methods of lymphotherapy to treat cancer, infection and autoimmune disease. | 2022-03-31 |
20220096616 | COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) - The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine. | 2022-03-31 |
20220096617 | ANTI-MALARIA COMPOSITIONS AND METHODS - Multilayer films comprise polypeptide epitopes from | 2022-03-31 |
20220096618 | AUTOTRANSPORTER-MEDIATED DISPLAY OF COMPLEMENT RECEPTOR LIGANDS BY BACTERIAL IMMUNOGENS - An approach for modifying multiple types of bacteria to produce surface modifications that enhance the immunologic response when used as a vaccine. A series of plasmids (pYF, pYFC, pYFP, pSF, pSPF, and pSCF) may be used to transform bacteria which then produce surface-exposed ligands that bind to complement receptors on antigen presenting cells. When modified bacteria are used as a vaccine, the vaccine recipients produce significantly higher titers of specific antibodies and are better protected against challenges from the disease-causing bacteria. | 2022-03-31 |
20220096619 | GLYCOCONJUGATION PROCESSES AND COMPOSITIONS - The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions. | 2022-03-31 |
20220096620 | FOOT-AND-MOUTH DISEASE VIRUS-LIKE PARTICLE ANTIGEN, AND VACCINE COMPOSITION, PREPARATION METHOD, AND APPLICATION THEREOF - The present disclosure provides a type O foot-and-mouth disease virus-like particle antigen, wherein the type O foot-and-mouth disease virus-like particle antigen is type O CATHAY type foot-and-mouth disease virus-like particle antigen, and the type O CATHAY type foot-and-mouth disease virus-like particle antigen is assembled by VP0, VP3 and VP1 antigen proteins of type O CATHAY type foot-and-mouth disease virus. The type O foot-and-mouth disease virus-like particle antigen of the present disclosure has good immunogenicity. The prepared vaccine can produce complete protection against the O-type foot-and-mouth disease virus on the 14th day after immunization. The antibody titer produced is higher than that of the commercial inactivated vaccine, and the duration of immune protection can be maintained for at least 133 days. The disclosure also relates to the prepared vaccine composition, preparation method and use thereof. | 2022-03-31 |
20220096621 | HEAT-RESISTANT H1N1 SUBTYPE INFLUENZA VIRUS MUTANT STRAIN, PREPARATION METHOD AND APPLICATION THEREOF - A heat-resistant H1N1 subtype influenza virus mutant strain rPR8-HA-N5 has been preserved at China Center for Type Culture Collection, Wuhan University, Wuhan, China with the preservation number of CCTCC No. V202043. | 2022-03-31 |
20220096622 | Compositions and Methods for Inducing Protective Immunity Against Human Immunodeficiency Virus Infection - Compositions, vaccines and methods for inducing an immunity, including a protective immunity, against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more adenovirus 26 vectors using for priming immunization and an isolated HIV antigenic polypeptide in combination with one or more MVA vectors for boosting immunization induced strong protective immunity against infections by one or multiple clades of HIV. | 2022-03-31 |
20220096623 | CORONAVIRUS-TARGETING UNIVERSAL DC CELL VACCINE, AND PREPARATION METHOD AND USE THEREOF - The present invention provides a method for preparing a coronavirus-targeting universal DC cell vaccine, and belongs to the technical field of virus vaccine preparation. The preparation method includes the following steps: ligating a fusion gene including a HLA gene and a coronavirus antigen gene onto an expression vector to obtain a recombinant vector; then transferring the recombinant vector into antigen-presenting cells to be transfected to obtain the coronavirus-targeting universal DC cell vaccine. The universal DC cell vaccine of the present invention has a targeting property against a coronavirus, can effectively stimulate a CTL, and has a killing effect on a target cell. | 2022-03-31 |
20220096624 | EXTRACELLULAR VESICLES HARBORING A SPIKE PROTEIN, NUCLEIC ACIDS FOR PRODUCING THE SAME, AND METHOD OF IMMUNIZING A SUBJECT AGAINST SARS-CoV-2 USING THE SAME - A nucleic acid including (i) a sequence of a S gene coding for a Spike protein and (ii) a sequence coding for a pilot peptide which interacts with ESCRT proteins. Also, extracellular vesicles, in particular exosomes, harboring at their external surface a Spike protein, obtainable by transfecting cells with the nucleic acid. Further, a method of immunizing a subject against a virus of the Orthocoronavirinae subfamily, in particular against SARS-CoV-2, by DNA prime-protein boost using the nucleic acid and the extracellular vesicles of the invention. | 2022-03-31 |
20220096625 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA - The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided. | 2022-03-31 |